• 1
    Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2008: 280-288.
  • 2
    Swerdlow SH, Campo E, Harris NL, eds. WHO classification of Tumors of Hematopoietic and Lymphoid Tissues.4th ed. Lyon, France: IARC Press; 2008.
  • 3
    Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2011; 29: 1876-1884.
  • 4
    Savage KJ, Harris NL, Vose JM, et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 103: 3152-3158.
  • 5
    Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood. 1998; 92: 76-82.
  • 6
    Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26: 4124-4130.
  • 7
    Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011; 117: 6756-6767.
  • 8
    Nademanee A, Palmer JM, Popplewell L, et al. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. Biol Blood Marrow Transplant. 2011; 17: 1481-1489.
  • 9
    Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol. 2003; 21: 2466-2473.
  • 10
    Pescarmona E, Pignoloni P, Puopolo M, et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol. 2001; 195: 361-366.
  • 11
    Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 2004; 104: 1940-1951.
  • 12
    Zinzani P, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000; 18: 2615-2619.
  • 13
    Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
  • 14
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma: NCI-Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244-1253.
  • 15
    Kaplan B, Jie T, Diana R, et al. Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection. Am J Transplant. 2010; 10: 1316-1319.
  • 16
    Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 17
    Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma [serial online]. ISRN Hematol 2011: 623924, 2011.
  • 18
    Crump M, Shepherd L, Lin B. A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by post-transplantation rituximab maintenance therapy versus observation for treatment of aggressive B-cell and T-cell non-Hodgkin's lymphoma. Clin Lymphoma. 2005; 6: 56-60.
  • 19
    Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104: 634-641.
  • 20
    Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12: 1169-1176.
  • 21
    Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008; 19: 958-963.
  • 22
    Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-r-ABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010; 151: 159-166.
  • 23
    Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009; 27: 106-113.
  • 24
    d'Amore F, Relander T, Lauritzsen GF, et al. High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T-cell lymphoma—final analysis of a large prospective multicenter study (NLG-T-01) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011; 118. Abstract 331.
  • 25
    Kim JG, Sohn SK, Chae YS, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol. 2006; 58: 35-39.
  • 26
    Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007; 110: 2316-2323.
  • 27
    Damaj G, Gressin R, Bouabdallah K. et al. Preliminary results from an open-label, multicenter, phase II study of bendamustine in relapsed or refractory T-cell lymphoma from the French GOELAMS group: the Bently Trial [abstract]. Ann Oncol. 2011; 22(suppl 4). Abstract 126.
  • 28
    O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29: 1182-1189.
  • 29
    Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30: 631-636.
  • 30
    Kim SJ, Kim K, Park Y, et al. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest New Drugs. 2012; 30: 368-375.
  • 31
    Arkenau HT, Chong G, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica. 2007; 92: 271-272.
  • 32
    Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004; 103: 2920-2924.
  • 33
    Klimecki W, Futscher B, Grogan T, et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994; 83: 2451-2458.
  • 34
    Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci. 2010; 31: 246-254.
  • 35
    Rittierodt M, Harada K. Repetitive doxorubicin treatment of glioblastoma enhances the PGP expression: a special role for endothelial cells. Exp Toxicol Pathol. 2003; 55: 39-44.
  • 36
    Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002; 62: 3387-3394.